According to PPI network analyses, TNF, IL6, AKT1, ACTB, IL1B, PPARG, PPARA, LPL, ESR1, and PTGS2 were the top 10 targets for HJJPD to treat NAFLD. Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.